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Abstract
Familial Amyloidotic Polyneuropathy (FAP) is a disorder characterized by the extracellular deposition of fibrillar
Transthyretin (TTR) amyloid, with a special involvement of the peripheral nerve. We had previously shown that dox-
ycycline administered for 3 months at 40 mg/Kg/ml in the drinking water, was capable of removing TTR amyloid
deposits present in stomachs of old TTR-V30M transgenic mice; the removal was accompanied by a decrease in
extracellular matrix remodeling proteins that accompany fibrillar deposition, but not of non-fibrillar TTR deposition
and/or markers associated with pre-fibrillar deposits. On the other hand, Tauroursodeoxycholic acid (TUDCA), a bili-
ary acid, administrated to the same mouse model was shown to be effective at lowering deposited non-fibrillar
TTR, as well as the levels of markers associated with pre-fibrillar TTR, but only at young ages.
In the present work we evaluated different doxycycline administration schemes, including different periods of treat-
ment, different dosages and different FAP TTR V30M animal models. Evaluation included CR staining, immunohisto-
chemistry for TTR, metalloproteinase 9 (MMP-9) and serum amyloid P component (SAP). We determined that a
minimum period of 15 days of treatment with a 8 mg/Kg/day dosage resulted in fibril removal. The possibility of
intermittent treatments was also assessed and a maximum period of 15 days of suspension was determined to
maintain tissues amyloid-free. Combined cycled doxycycline and TUDCA administration to mice with amyloid
deposition, using two different concentrations of both drugs, was more effective than either individual doxycycline
or TUDCA, in significantly lowering TTR deposition and associated tissue markers. The observed synergistic effect of
doxycycline/TUDCA in the range of human tolerable quantities, in the transgenic TTR mice models prompts their
application in FAP, particularly in the early stages of disease.
Introduction
Familial Amyloid Polyneuropathy (FAP) is characterized by
the deposition of Transthyretin (TTR) amyloid fibrils in
several organs, with special involvement of the peripheral
nerve. Therapy is presently based on liver transplantation in
selected patients, although progression of amyloid cardio-
myopathy after liver transplantation is a serious and
unsolved concern. FAP is characterized by early impairment
of temperature and pain sensation in the feet, autonomic
dysfunction leading to malabsorption and emaciation. Amy-
loid deposits can occur in any part of the peripheral
nervous system, including nerve trunks, plexus and sensory
and autonomic ganglia. TTR V30M is the most common
TTR mutation associated with FAP but over 100 mutations
are identified and associated with disease [1].
Animal models for a variety of disorders have been
widely used to investigate mechanisms leading to disease
and to assess possible therapeutic strategies. Therefore, a
number of models have been created for FAP, including
mice carrying the most prevalent TTR mutation, V30M,
under the control of different promoters [2,3], and a
highly amyloidogenic TTR variant, L55P [4]. The charac-
terization of these models revealed early presence of
non-fibrillar TTR that with aging evolved to TTR amy-
loid deposits [4], thus mimicking the human pathological
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characteristics, except for the lack of deposits in the per-
ipheral nerve. Very recently, another FAP mouse model
was generated, the V30M transgenic mice in a heat shock
factor 1 (HSF-1) null background, representing a step
forward in the study of this disorder; these mice repre-
sent an improved FAP model since animals showed TTR
deposition in extra-neural and neural tissues, and recapi-
tulated pathological findings in FAP. Amyloid deposition
occurred in the peripheral and autonomic nervous sys-
tems and induction of pro-inflammatory cytokines, up-
regulation of the receptor for advanced glycation end
products (RAGE) and NF-B activation were evident in
the dorsal root ganglia and peripheral nerve presenting
TTR deposits. Deposition did not occur in the brain and
spinal cord; furthermore, a significant decrease in unmye-
linated fibers occurred when fibrillar material was depos-
ited in nerve [5].
While several reports describe the use of different
therapeutic strategies in mouse models for neurodegen-
erative disorders such as Huntington disease (HD) [6],
Parkinson’s disease, Alzheimer’s disease (AD) [7], Prion
disease [8] and other, in vivo assessment of potential
therapies has not been fully exploited in FAP mouse
models. Doxycycline shown as a TTR fibril disrupter in
vitro [9], when tested in transgenic TTR V30M mice,
was capable of disaggregating amyloid deposits with
concomitant decrease of metalloproteinase 9 (MMP-9),
tissue inhibitor of metalloproteinase (TIMP-1), serum
amyloid P component (SAP) and neutrophil gelatinase-
associated lipocalin NGAL [10,11]. However, doxycy-
cline was unable to remove non-fibrillar TTR or to
lower non-fibrillar TTR-associated markers. On the
other hand, Tauroursodeoxycholic acid (TUDCA), a bili-
ary acid acting as a potent anti-apoptotic and anti-oxi-
dant was also evaluated in TTR-V30M transgenic mice.
Decreased apoptotic and oxidative biomarkers usually
associated with TTR deposition, namely the ER stress
markers BiP and eIF2alpha, the Fas death receptor and
oxidation products such as 3-nitrotyrosine were signifi-
cantly lowered. Most importantly, TUDCA treatment
significantly reduced TTR toxic aggregates in as much
as 75% [12]. However, TUDCA efficiency was only evi-
dent in young mice displaying non-fibrillar TTR depos-
its, i.e., in the absence of amyloid deposits. In the
present work we assessed the efficiency of different dox-
ycycline and TUDCA concentrations, either in indivi-
dual or combined regimens, to lower TTR deposits and




All animals were kept and used strictly in accordance
with national rules and European Communities Council
Directive (86/609/EEC), and all studies performed were
approved by the Portuguese General Veterinarian Board
(authorization number 024976 from DGV- Portugal).
Transgenic mice for human V30M TTR in a TTR null
background, thereafter referred to as the TTR model,
were kindly provided by Professor Suichiro Maeda from
Yamanashi University. These animals were previously
analyzed in our laboratory and ~60% of the animals
over 1 year of age were found to have TTR deposition
as amyloid, i.e., Congo red (CR)-positive material [4],
having non-fibrillar TTR deposits at younger ages. Mice
expressing human TTR V30M in a TTR null back-
ground heterozygous for the heat shock transcription
factor 1 (Hsf1), thereafter referred to as the TTR/HSF
mice model, were recently characterized and shown to
have early non-fibrillar TTR deposition as compared to
TTR mice, evolving to amyloid deposits in several
organs and tissues including the peripheral nervous sys-
tem [5].
For each model, 7- 15 animals with ages ranging
from 16-25 months were treated with doxycycline
(Sigma), at concentrations of 40 or 8 mg/Kg/day,
administrated in the drinking water, protected from
light and changed once a week. Mice were treated
either for 1 month or 15 days and sacrificed just after
the treatment period, or after an interruption of 15, 30
or 45 days (see table 1). Mice receiving water alone
were used as controls.
In other instances, TTR mice 17-21 months (7-9 ani-
mals) were treated in alternated cycles with doxy-
cycline/TUDCA: doxycycline was administrated for
15 days at 40 or 8 mg/Kg/day followed by TUDCA
(Calbiochem) administration, also in the drinking
water, for 30 days at 500 or 50 mg/Kg/day; this regi-
men was performed twice in a total treatment period
of three months. Non-treated mice or treated with the
individual drugs for the same time period were used as
controls.
Animals were killed after anesthesia with ketamine/
xylazine. Esophagus, stomach, small and large intestines
were immediately excised and processed. Tissues were
fixed in 4% neutral buffered formalin and embedded in
paraffin or immediately frozen, for light microscopy or
for total protein extraction, respectively.
CR staining
The presence of amyloid in tissue sections was investi-
gated after staining with Congo red and observation
under polarized light [13]. Briefly, deparaffinized tissues
sections were incubated for 20 min with 80% ethanol
saturated with NaCl followed by 0.5% Congo red in 80%
ethanol saturated with NaCl, and analyzed under polar-
ized light. Amyloid was identified by the characteristic
green birefringence.
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Immunohistochemistry (IHC)
5 μm-thick sections were deparafinated in xylol and
dehydrated in a descendent alcohol series. Endogenous
peroxidase activity was inhibited with 3% hydrogen per-
oxide/100% methanol and sections were blocked in 4%
bovine serum and 1% bovine serum albumin in phos-
phate buffered solution (PBS). Primary antibodies used
were rabbit polyclonal anti- TTR (Dako, 1:1000), rabbit
polyclonal anti-MMP-9 (Abcam, 1:1500), sheep polyclo-
nal anti-SAP (a kind gift from the laboratory of Profes-
sor Pepys, Royal Free Hospital, London, 1:2000), rabbit
polyclonal anti-biglycan (a kind gift from Dr P. Rough-
ley, Shriners Hospitals, McGill University, Montreal,
Canada,1:1000), goat anti-BiP (St Cruz, 1:50), rabbit
polyclonal anti-Fas (St Cruz, 1:200), and rabbit polyclo-
nal anti-3-nitrotyrosine (Chemicon, 1:500), which were
diluted in blocking solution and incubated overnight at
4°C. Antigen visualization was performed with the bio-
tin-extravidin-peroxidase kit (Sigma), using 3-amino-9-
ethyl carbazole (Sigma) or diaminobenzidine as sub-
strates. Semiquantitative immunohistochemistry analysis
was carried out with the Universal Imaging system
(NIH, Bethesda, MD) which performs automated
particle analysis in a measured area, that is, the area
occupied by pixels corresponding to the immunohisto-
chemical substrate’s color is counted and normalized
relatively to the total area. Each slide used was analyzed
in 5 different selected areas. Results shown represent %
occupied area ± SD.
Western blot
For western blot, frozen stomachs from 3 animals from
each group were homogenized in PBS, pH 7.4 and total
protein quantified using the Bio-Rad protein assay (Bio-
Rad Laboratories); then 30 μg of each extract was run
per lane, separated in a 12% SDS-PAGE gel and proteins
transferred into a nitrocellulose membrane. Immunode-
tection was performed with rabbit polyclonal anti-BiP
(Abcam, 1:500) and mouse anti-actin (1:1000, Sigma)
antibodies; detection was performed with ECL®
(enhanced chemiluminescence; GE Healthcare). Quanti-
fication of BiP levels was performed by densitometry
using the ImageQuant 5.1 software (Molecular
Dynamics). Density values were normalized with b-actin
expression. Results are presented as normalized
density ± SD.
Statistical analyses
All data examined were expressed as mean ± S.E. Com-
parison between groups was made using the ANOVA
test. A p value of less than 0.05 was considered statisti-
cally significant.
Results
1. Doxycycline administration schemes
a. Different doxycycline periods in the TTR/HSF model
To address the importance of doxycycline as a TTR
fibril disrupter and its use in future therapeutic
approaches, we tested the initial described dosage (40
mg/Kg/day) in the TTR/HSF mice and decreased the
period of treatment to 1 month.
As previously reported [11], CR staining is limited to
very small and restricted areas, whereas MMP-9 staining
although easily visualized, is usually either positive or
negative; thus, in both cases we did not proceed to
quantitative analysis, and instead we show the results as
Table 1 Different doxycycline treatment schemes, including duration of treatment, concentrations and mice models
used












1 month 40 TTR/
HSF
19 2/10 6/8 0/10 5/10
15 days 40 TTR/
HSF
26 2/10 7/8 2/10 3/7




20 8/10 6/8 5/10 4/8




23-25 0/10 10/10 0/10 8/10
15 days 8 TTR/
HSF
16-18 1/7 9/10 1/7 8/10




16-18 8/12 4/4 7/12 3/7




20 4/10 7/8 1/10 4/8
15 days + 15 days
interruption
8 TTR 22 2/15 6/8 2/15 4/8
Ratios between the number of animals which showed positive staining for MMP-9 and CR and the total number of mice used in each group are shown.
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a percentage of positive relative to the total number of
analyzed cases. Analysis of CR birefringence and MMP-
9 positive cases indicated that doxycycline was able to
act on amyloid deposits since no amyloid was found and
MMP-9 positive slides were observed only in 20% of the
mice (table 1). In the control group, MMP-9 and CR
positive cases were found in 75% and 50% of the ani-
mals, respectively. We then repeated the experiment for
a period of 15 days to determine if this drug was still
able to act on amyloid in a shorter period of time. As
reported in table 1, 15 days were sufficient to lower
MMP-9 expression to negligible levels and to disaggre-
gate amyloid, since only 20% of the animals were posi-
tive for these two markers, whereas non-treated mice
showed considerable MMP-9 staining (87.5% of the
mice) and amyloid (57% of the animals).
b. Testing various treatment intervals
Our studies were continued by performing doxycycline
administration at 40 mg/Kg/day, followed by interrup-
tion of treatment for different periods of time, in TTR/
HSF mice. A pause of 45 days after doxycycline admin-
istration for 15 days, did not maintain amyloid disaggre-
gation as indicated by the observation of MMP-9
immunoreactivity and the presence of amyloid deposits
in 80% and 50%, respectively, of the treated mice, com-
parable to the control group which showed values of
75% and 50% for these parameters, respectively. How-
ever, suspension of treatment for 30 days resulted in
sustained negligible levels of MMP-9 and CR in all trea-
ted mice (table 1), while non-treated animals had signifi-
cant amounts of both MMP-9 and amyloid in 100% and
80% of mice, respectively.
c. Testing different dosages of doxycycline
Due to the observation that 15 days were sufficient for
doxycycline to act on amyloid deposits in mice tissues,
we reasoned that a lower dosage would also be active.
Doxycycline at 8 mg/Kg/day administrated to TTR/HSF
mice for 15 days revealed sufficient to lower MMP-9
and to remove amyloid, as only 14.3% of the animals
were positive for both markers (table 1). 90% and 80%
were the values found in the control group for these
markers, respectively (not shown). However, when using
this dosage, suspension of treatment for 30 days resulted
in MMP-9 immunoreactivity in 66.7% of the animals
and in the presence of amyloid in 58.3% (table 1), simi-
lar to values found in the control group, respectively. In
the light of these results, we next reduced the suspen-
sion period for 15 days and found positive staining for
MMP-9 only in 40% of animals and congophilic material
in only 10% of the mice, indicative of reasonably effec-
tive treatment at reducing the amyloid load.
Evaluation of this regimen, i.e., 8 mg/Kg/day in 2 week
cycles (15 days of treatment followed by 15 of interrup-
tion) was then performed in the TTR model. As
reported in figure 1 and table 1, CR birefringence and
MMP-9 staining revealed negative for the great majority
of the treated animals, in opposition to the non-treated
mice that showed positivity for both markers (see figure
1). Furthermore, SAP known to be associated to amyloid
deposits was also negligible in treated mice, whereas
non-treated animals showed, as expected, significant
levels which mostly co-localized to congophilic amyloid
deposits (figure 1). No significative changes were seen in
non-fibrillar TTR deposits between treated and non-
treated mice (figure 1).
2. Combined treatment with doxycycline and TUDCA
As we know that TUDCA is able to lower non-amyloid
TTR deposits in young mice, we therefore hypothesized
that a doxycycline/TUDCA combined treatment may be
synergistic in lowering both fibrillar and non-fibrillar
deposits.
a. High dosages
Doxycycline and TUDCA were cyclically administrated
to TTR transgenic mice: doxycycline at 40 mg/kg/day
for 15 days, followed by TUDCA at 500 mg/Kg/day for
30 days. This cycle was repeated twice; then tissues
were analyzed for TTR deposition as well as for other
FAP markers related to ECM remodeling, oxidative
stress, cellular death, and ER stress, and compared with
age-matched non-treated or single treated animals
(either with doxycycline or TUDCA).
Regarding evaluation of amyloid deposition and ECM
integrity, we measured MMP-9 and CR positivity, CSPG
and biglycan levels. Table 2 summarizes the results
obtained for CR and MMP-9 staining in the stomach.
No amyloid was observed in doxycycline treated ani-
mals, either in doxycycline/TUDCA or doxycycline regi-
mens, which is expected and attributed to ability of this
drug to disaggregate amyloid fibrils. The combined
treatment had a pronounced effect on MMP-9 detec-
tion, as compared to doxycycline treatment alone (29%
and 40%, respectively, table 2). TUDCA treatment did
not alter the levels of this metalloproteinase which was
equivalent to control non-treated animals. CSPG, pre-
viously established to be elevated in the TTR model in
old mice presenting amyloid deposits [11], was now
evaluated in the context of the combined doxycycline/
TUDCA treatment. Results are depicted in figure 2 and
showed that the combination of the 2 drugs was able to
significantly decrease CSGP levels, whereas TUDCA or
doxycycline alone were not able to change high CSPG
levels, as compared to the control (figure 2, left panels).
Biglycan is elevated both in FAP patients and in FAP
mice models early in disease development, before amy-
loid is evident. Our previously reported data showed
that doxycycline administration does not result in bigly-
can decrease probably because doxycycline being a fibril
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disrupter is not able to counteract pre-fibrillar TTR hav-
ing no impact on biglycan levels. However, assessment
of biglycan levels by IHC (figure 2, right panels) in the
combined doxycycline/TUDCA treated mice revealed
lower than in control (untreated mice), or in doxycy-
cline alone (as expected) or in animals treated with
TUDCA alone. Taken together, our observations
indicated that combined administration of doxycycline/
TUDCA is a strong therapy for ECM derangement, as
all tested markers were restored to basal levels.
At this point, it was imperative to assess levels of
other markers, related to oxidative stress, ER stress and
cellular death, markers not affected by doxycycline treat-
ment or by TUDCA at old ages. Above all, it was
Figure 1 Immunohistochemistry and Congo Red analysis of stomachs from TTR mice treated with doxycycline. Doxycycline was
administered in the drinking water (8 mg/Kg/day) for 15 days followed by a suspension period of 15 days (water alone) after which animals
were sacrificed, (n = 15); control mice were given water alone (n = 11). The top 2 panels represent CR analyses (arrow pointing at CR
birefringence in a non-treated mouse) and MMP-9 IHC. The bottom 2 panels are representative of SAP (arrow pointing at staining which co-
localizes with amyloid in a non-treated mouse) and TTR IHC. Scale bar (CR and SAP = 100 μm; MMP-9 and TTR = 200 μm).
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necessary to assess extracellular deposition of TTR by
immunohistochemistry in organs most affected with
deposition. Figure 3 displays representative images of
the results obtained and clearly shows that TTR deposi-
tion is significantly decreased in mice submitted to the
high doxycycline/TUDCA dose combined treatment. On
the contrary, mice subjected to either doxycycline or
TUDCA administration presented, at the end of the
experiment, TTR loads comparable to non-treated ani-
mals. As for nitrotyrosine, Fas and Bip, results indicated
that all were significantly decreased only in mice receiv-
ing high doses of the combined treatment (figure 4).
Analysis of other organs with characteristic TTR deposi-
tion, such as esophagus and intestine, revealed the same
pattern, i.e., individual treatments with either doxycy-
cline or TUDCA were not effective at lowering these
markers, whereas the combined treatment was (not
shown). Finally, and to confirm the IHC results, we also
analyzed BiP levels by western blot, after protein extrac-
tion from frozen stomachs (figure 5), and confirmed the
IHC results.
b. Low dosages
At this point we had verified the benefits of the cycled
administration of doxycycline and TUDCA, and thus it
was appropriate to test lower dosages of this combina-
tion. As for doxycycline and as described in the first
sections of results, dosages of 8 mg/Kg/day were still
effective in removing TTR amyloid. Regarding TUDCA,
and although we did not perform dosage testing, we
selected a dose of 50 mg/Kg/day as it corresponds to
human admissible/tolerable dosages. Administration was
performed as before, with combination of 2 cycles of
doxycycline administrated for 15 days, followed by
TUDCA for 30 days. Tissues with characteristic TTR
deposition were processed and analyzed for the estab-
lished markers. Because the dosage/period of adminis-
tration/suspension for doxycycline had been well studied
and determined, we were confident that this treatment
resulted in the removal of amyloid and in ECM recov-
ery, and thus we analyzed only MMP-9 reactivity. In the
combined treatment, MMP-9 immunoreactivity was
reduced in 33% of the mice, in opposition to 71% of
positive control animals, indicative of tissue improve-
ment at the ECM level in most animals.
In figures 3 and 4 we show representative images of
the results with quantification of TTR deposition (figure
3) and of BiP, Fas and 2-nitrotyrosine levels (figure 4),
as assessed by IHC. The quantification of staining
clearly showed that levels of these 4 markers were sig-
nificantly lowered in the combined treatment as com-
pared to the non-treated or to individual doxycycline or
TUDCA regiments, as easily concluded by comparing
tissue staining intensity (histograms, figures 3 and 4).
The decrease in TTR deposition and associated biomar-
kers was not as impressive in the lower dosages, which
are equivalent to a clinical setting, as compared to the
higher doses, indicating a dose response behavior that is
still efficient.
Discussion
The mechanism underlying FAP pathology is not com-
pletely understood and important insights arose from
studies on FAP mice models and clinical samples.
Transgenic mice, for instance, showed that TTR first
presented as extracellular non-fibrillar deposits (lacking
the characteristic CR birefringence) which were asso-
ciated with increased levels of biomarkers also observed
in biopsies of asymptomatic carriers of the V30M TTR
mutation, such as 3-nitrotyrosine, Fas, BiP and others
[12]. Old mice present both non-fibrillar deposits and
TTR amyloid, indicative of a kinetic evolution between
these two amyloidogenic species. Although this model
does not present peripheral nerve involvement, the hall-
mark of the human pathology, it created the possibility
to test the efficacy of several drugs in vivo. In fact, the
knowledge acquired in the last years concerning the
identification of intermediate species and the mechan-
isms underlying amyloidosis paved the way for the
investigation of drugs capable of interfering with the
amyloidogenic pathway, at different stages. One of such
class of drugs are amyloid fibril disrupters such as doxy-
cycline, expected to function in all amyloid fibril types,
independently of their protein/peptide precursor.
In this work we proposed to use the TTR animal
models to optimize doxycycline therapeutic regimen in
vivo; in order to achieve this goal we tested three differ-
ent drug concentration and different periods of adminis-
tration, including different suspension times. We also
used two different models, the TTR and the TTR/HSF
model and concluded that a dose of 8 mg/Kg/day and a
maximum of 15 days maintained fibril disaggregation.
In spite of the positive and exciting results obtained
with this drug, doxycycline is not able to decrease all
the FAP markers, and therefore we inferred that it
Table 2 Analysis of CR and MMP-9 patterns in the
stomach of TTR mice
Mice group/Marker CR positive Positive MMP-9








The values refer to the percentage of positive related to total analyzed cases
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would not perform optimally as a therapy for FAP. As
TUDCA is effective in reducing TTR load in young
TTR mice, in this work we also explored the potential
of two drugs, doxycycline and TUDCA, and found a
synergistic effect as combined cycled administration of
both drugs was clearly beneficial to lower TTR
deposition and all the biomarkers under study, whereas
single individual drug administration failed to produce
improvement of all of the markers evaluated. Recent
data demonstrated clearly activation of the classical UPR
pathways in FAP tissues not specialized in TTR synth-
esis but presenting extracellular TTR aggregate and
Figure 2 Immunohistochemistry analyses for CSPG and biglycan in stomachs from TTR mice treated with doxycycline and TUDCA.
Groups of animals analyzed: control mice (control, upper row) (n = 7); then in the descending rows: mice receiving doxycycline alone (40 mg/
Kg/day; n = 9); mice receiving TUDCA alone (500 mg/Kg/day; n = 7); mice receiving either high dosages of doxycycline/TUDCA (40 mg/Kg/day
and 500 mg/Kg/day, respectively; n = 7). The combined scheme involved the administration of the referred dosage of doxycycline for 15 days,
followed by the administration of the referred dosage of TUDCA for 30 days. The cycle was repeated twice; for the individual drug
administration, during the interruption periods, mice were receiving water alone. Scale bar = 200 μm; Histogram: quantification of the levels of
the referred markers, as described in material and methods.*P < 0.05.
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fibril deposition [14]. More recently, we showed that
TUDCA reduces BiP induction in TTR mice [12]. The
ability of TUDCA to abolish ER stress was previously
observed and reduction of BiP induction and caspase 12
activation were reported [15]; TUDCA is also able to
protect against oxidative stress in tissues damaged by
TTR deposition and thus, TUDCA can act at different
levels, affecting TTR extracellular deposition. It has
been suggested that a possible mechanism for TTR
extracellular aggregation is the influence of secreted
metabolites generated by oxidative stress and apoptosis
on TTR aggregation [12]. By intervening at an early
point in the apoptosis pathway and preventing the
transfer of Bax to the mitochondria, TUDCA has the
potential to save certain kinds of cells from early death
(for a review see [16]). Doxycycline besides its ability to
disrupt TTR amyloid fibrils, is known to be a matrix
metalloproteinase inhibitor, and can in this way contri-
bute to lower inflammation generated by the extracellu-
lar deposits [17]. MMP-9 is highly expressed at sites of
inflammation and contributes to the pathogenesis of
various chronic inflammatory diseases. In asthma,
MMP-9 is upregulated and involved in remodeling pro-
cesses [18-20]. Furthermore, Pycnogenol, an anti-inflam-
matory drug is able to attenuate signs of inflammation
in asthma patients through reduction of MMP-9 secre-
tion [21]. It is also established that the ER-mediated
stress response contributes to inflammation [22]. In fact,
an ER-stress-inflammation loop has been proposed [23];
in this way, TUDCA and doxycycline acting together
may overcome each other limitations producing syner-
gistic effects, by acting in a cascade that lowers inflam-
matory stress and ultimately results in TTR removal and
tissue improvement.
Both doxycycline and TUDCA are safe drugs, and
have been used in different clinical settings. TUDCA
has been used in nutrition-associated liver disease [24],
and other liver conditions, and highly assessed in the
context of neurodegenerative disorders, especially in
animal models of Huntington disease [16]. Doxycy-
cline, besides its wide application as an antibiotic,
is being used in human studies namely in aneurysm
and vascular conditions [25-27] and also in multiple
sclerosis [28].
Figure 3 Immunohistochemistry analyses for TTR in stomachs from TTR mice treated with doxycycline and TUDCA. Groups of animals
analyzed: in the upper row: control mice (n = 7); mice receiving doxycycline alone (40 mg/Kg/day; n = 9); mice receiving TUDCA alone (500
mg/Kg/day; n = 7); in the lower row: mice receiving either high dosages of doxycycline/TUDCA (40 mg/Kg/day and 500 mg/Kg/day,
respectively; n = 7) or receiving low dosages of doxycycline/TUDCA (8 mg/Kg/day and 50 mg/Kg/day, respectively; n = 8). The combined
scheme involved the administration of the referred dosage of doxycycline for 15 days, followed by the administration of the referred dosage of
TUDCA for 30 days. The cycle was repeated twice; for the individual drug administration, during the interruption periods, mice were receiving
water alone. Scale bar = 200 μm; Histogram: quantification of the levels of the referred marker, as described in material and methods.*P < 0.05.
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Figure 4 Immunohistochemistry analyses for nitro, Fas and BiP in stomachs from TTR mice treated with doxycycline and TUDCA.
Groups of animals analyzed: control mice (control, upper row) (n = 7); then in the descending rows: mice receiving doxycycline alone (40 mg/
Kg/day; n = 9); mice receiving TUDCA alone (500 mg/Kg/day; n = 7); mice receiving either high dosages of doxycycline/TUDCA (40 mg/Kg/day
and 500 mg/Kg/day, respectively; n = 7) or receiving low dosages of doxycycline/TUDCA (8 mg/Kg/day and 50 mg/Kg/day, respectively; n = 8).
The combined scheme involved the administration of the referred dosage of doxycycline for 15 days, followed by the administration of the
referred dosage of TUDCA for 30 days. The cycle was repeated twice; for the individual drug administration, during the interruption periods,
mice were receiving water alone. Scale bar = 200 μm; Histogram: quantification of the levels of the referred markers, as described in material
and methods.*P < 0.05.
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Using the principle of interspecies drug dose scaling
[29], and considering a standard body weight of 70 kg
in man and 20 g in mouse, the ratio (Whuman /Wanimal )
0.7 = 302.58. Therefore the TUDCA dose of 50 mg/kg in
mouse corresponds to 302.58 mg/day in man, and the
TUDCA dose of 500 mg/kg corresponds to 3025.8 mg
of TUDCA in man. The TUDCA recommended dose in
man is 250-750 mg/day. Furthermore TUDCA is very
well tolerated as the DL50 in mouse is 3.000 mg/Kg.
Similarly, 8 mg/Kg/day of doxycycline in mouse corre-
sponds to 48 mg/day in man, and the 40 mg/Kg/day
dosage in mouse corresponds to 242 mg/day in man,
largely within the human therapeutic ranges.
Based on this data we propose an open-label study for
TTR amyloid patients with oral administration of
doxycycline (200 mg/day) and TUDCA (750 mg/day), to
evaluate efficacy, tolerability, safety and pharmacokinetics.
Acknowledgements
We thank Rossana Correia for tissue processing; This work was supported by
grant PIC/IC/82824/2007 from Foundation for Science and Technology,
Portugal (FCT), and Euramy EU Project - 6th FP- Contract 037525.
Author details
1Molecular Neurobiology Unit, IBMC- Instituto de Biologia Molecular e
Celular, Rua do Campo Alegre 823, 4150-180 Porto, Portugal. 2Escola
Superior de Tecnologia da Saúde do Porto, Instituto Politécnico do Porto,
Rua Valente Perfeito 322, 4400-330 Vila Nova de Gaia, Portugal. 3Amyloidosis
Research and Treatment Center , Fondazione IRCCS Policlinico San Matteo
and Department of Biochemistry, University of Pavia P. le Golgi, 19, 27100
Pavia, Italy. 4ICBAS- Instituto de Ciências Biomédicas Abel Salazar, Largo Prof.
Abel Salazar, 2, 4099-003 Porto Portugal.
Authors’ contributions
IC participated in the design of the study, carried out the
immunohistochemistry analysis for CSPG, biglycan and MMP-9, BiP western
blot, performed the statistical analysis and drafted the manuscript. DM
participated in animals sacrifice, organ collection and carried out
immunohistochemistry analysis for TTR, Fas, nitro and BiP. TR participated in
mouse colony maintenance, drug administration animal sacrifice and organ
collection, and CR analysis. GM participated in the design of the study. MJS
conceived the study, and participated in its design and coordination. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 April 2010 Accepted: 30 July 2010 Published: 30 July 2010
References
1. Benson MD, Kincaid JC: The molecular biology and clinical features of
amyloid neuropathy. Muscle Nerve 2007, 36:411-23.
2. Araki S, Shigehiro Y, Murakami T, Watanabe S, Ikegawa S, Takahashi K,
Yamamura K: Systemic amyloidosis in transgenic mice carrying the
human mutant transthyretin (met30) gene. Mol Neurobiol 1994, 8:15-23.
3. Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S, Shimada K,
Yamamura K, Araki S: Systemic amyloidosis in transgenic mice carrying
the human mutant transthyretin (Met30) gene. Pathologic similarity to
human familial amyloidotic polyneuropathy, type I. Am J Pathol 1991,
138:403-12.
4. Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ: Evidence
for early cytotoxic aggregates in transgenic mice for human
transthyretin. Am J Pathol 2002, 161:1935-48.
5. Santos SD, Fernandes R, Saraiva MJ: The heat shock response modulates
transthyretin deposition in the peripheral and autonomic nervous
systems. Neurobiol Aging 2010, 31:280-9.
6. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W,
Ross CA, Duan W: Tiagabine is neuroprotective in the N171-82Q and R6/
2 mouse models of Huntington’s disease. Neurobiol Dis 2008, 30:293-302.
7. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J,
Lee JP, Chang KA, Kim S, Suh YH: Minocycline attenuates neuronal cell
death and improves cognitive impairment in Alzheimer’s disease
models. Neuropsychopharmacology 2007, 32:2393-404.
8. Riemer C, Burwinkel M, Schwarz A, Gültner S, Mok SW, Heise I, Holtkamp N,
Baier M: Evaluation of drugs for treatment of prion infections of the
central nervous system. J Gen Virol 2008, 89:594-7.
9. Cardoso I, Merlini G, Saraiva MJ: 4’-iodo-4’-Deoxydoxorubicin and
tetracyclines disrupt transthyretin amyloid fibrils in vitro producing non-
cytotoxic species. Screening for TTR fibril disrupters. FASEB J 2003,
17:803-9.
10. Cardoso I, Saraiva MJ: Doxycycline disrupts transthyretin amyloid:
evidence from studies in a FAP transgenic mice model. FASEB J 2006,
20:234-39.
Figure 5 Western blot analysis for BiP. Stomachs from mice
receiving combined cycled administration of doxycycline/TUDCA
(40 mg/Kg/day and 500 mg/Kg/day, respectively; n = 3), mice
receiving doxycycline (40 mg/Kg/day; n = 3), mice receiving TUDCA
(500 mg/Kg/day; n = 3), and control mice (n = 3). Histogram:
densitometry of BiP/actin band intensity, *P < 0.05.
Cardoso et al. Journal of Translational Medicine 2010, 8:74
http://www.translational-medicine.com/content/8/1/74
Page 10 of 11
11. Cardoso I, Brito M, Saraiva MJ: Extracellular Matrix markers in Familial
Amyloid Polyneuropathy: disease progression and follow-up of therapies
in a transgenic mouse model. Disease Markers 2008, 25:37-47.
12. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ: Anti-apoptotic
treatment reduces transthyretin deposition in a transgenic mouse
model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta
2008, 1782:517-22.
13. Puchtler H, Sweat F: Congo Red as a stain for fluorescence microscopy of
amyloid. J Histochem Cytochem 1965, 13:693-4.
14. Teixeira PF, Cerca F, Santos SD, Saraiva MJ: Endoplasmic reticulum stress
associated with extracellular aggregates. Evidence from transthyretin
deposition in familial amyloid polyneuropathy. J Biol Chem 2006,
281:21998-22003.
15. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE, Yoffe B: Effect
of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced
caspase-12 activation. Hepatology 2002, 36:592-601.
16. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM: Bile acids:
regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009,
50:1721-34.
17. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ: Deposition of
transthyretin in early stages of familial amyloidotic polyneuropathy:
evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001,
159:1993-2000.
18. Kelly EA, Jarjour NN: Role of matrix metalloproteinases in asthma. Curr
Opin Pulm Med 2003, 9:28-33.
19. Lee YC, Lee HB, Rhee YK, Song CH: The involvement of matrix
metalloproteinase-9 in airway inflammation of patients with acute
asthma. Clin Exp Allergy 2001, 31:1623-30.
20. Wenzel SE, Balzar S, Cundall M, Chu HW: Subepithelial basement
membrane immunoreactivity for matrix metalloproteinase 9: association
with asthma severity, neutrophilic inflammation, and wound repair. J
Allergy Clin Immunol 2003, 111:1345-52.
21. Grimm T, Chovanová Z, Muchová J, Sumegová K, Liptáková A, Duracková Z,
Högger P: Inhibition of NF-kappaB activation and MMP-9 secretion by
plasma of human volunteers after ingestion of maritime pine bark
extract (Pycnogenol). J Inflamm (Lond) 2006, 27:3-1.
22. Slodzinski H, Moran LB, Michael GJ, Wang B, Novoselov S, Cheetham ME,
Pearce RK, Graeber MB: Homocysteine-induced endoplasmic reticulum
protein (herp) is up-regulated in parkinsonian substantia nigra and
present in the core of Lewy bodies. Clin Neuropathol 2009, 28:333-43.
23. Zhang K, Kaufman RJ: From endoplasmic-reticulum stress to the
inflammatory response. Nature 2008, 454:455-62.
24. Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R Jr, Couser R,
Rhodes P: Tauroursodeoxycholic acid (TUDCA) in the prevention of total
parenteral nutrition-associated liver disease. J Pediatr 2002, 141:237-42.
25. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH,
Geelkerken RH, Lindeman JH: Doxycycline therapy for abdominal
aneurysm: Improved proteolytic balance through reduced neutrophil
content. J Vasc Surg 2009, 49:741-9.
26. Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT,
Guglielmo BJ, McCulloch CE, Young WL: Feasibility of minocycline and
doxycycline use as potential vasculostatic therapy for brain vascular
malformations: pilot study of adverse events and tolerance. Cerebrovasc
Dis 2008, 25:157-63.
27. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R:
Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in
patients with an abdominal aneurysm: doxycycline selectively depletes
aortic wall neutrophils and cytotoxic T cells. Circulation 2009, 119:2209-16.
28. Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E,
Jimenez JJ, Mauro L, Jy W, Smith SJ: Combination therapy with interferon
beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch
Neurol 2008, 65:199-204.
29. McCann UD, Ricaurte GA: Caveat emptor: editors beware.
Neuropsychopharmacology 2001, 24:333-6.
doi:10.1186/1479-5876-8-74
Cite this article as: Cardoso et al.: Synergy of combined Doxycycline/
TUDCA treatment in lowering Transthyretin deposition and associated
biomarkers: studies in FAP mouse models. Journal of Translational
Medicine 2010 8:74.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cardoso et al. Journal of Translational Medicine 2010, 8:74
http://www.translational-medicine.com/content/8/1/74
Page 11 of 11
